• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测前列腺活检 Gleason 评分的因素。

Factors predicting prostatic biopsy Gleason sum under grading.

机构信息

Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

DOI:10.1016/j.juro.2009.02.127
PMID:19447436
Abstract

PURPOSE

We determined clinical factors affecting the under grading of biopsy Gleason sum compared with prostatectomy pathology and developed a model predicting the probability of under grading.

MATERIALS AND METHODS

We analyzed a cohort of 1,701 patients treated for prostate cancer at our institution between 1988 and 2007 with complete biopsy and pathological data available. Patients with a biopsy Gleason sum of 7 or less were included in our analysis. Cases were categorized as under graded or not under graded by comparing biopsy and radical prostatectomy Gleason sums. Logistic regression was used to determine the predictors of under grading based on clinical variables (race, age at diagnosis, body mass index, prostate weight, diagnostic prostate specific antigen, biopsy positive-to-total core ratio, maximal cancer percent in positive cores and time from diagnosis to surgery). A nomogram was developed to calculate the probability of under grading. Results were validated using bootstrapping.

RESULTS

Under grading occurred in 46.6% of our cohort. Significant variables predicting under grading were age at diagnosis, biopsy Gleason sum, diagnostic prostate specific antigen, prostate weight, biopsy positive-to-total core ratio and maximal percent of cancer in cores (p <0.05). Nomogram predictive accuracy was 72.4%.

CONCLUSIONS

The risk of Gleason sum under grading can be predicted to a satisfactory level using our nomogram. Predicting under grading would improve patient consulting and identify those who should consider repeat biopsy, ultimately enhancing the accuracy of prostate cancer diagnosis.

摘要

目的

我们确定了影响活检 Gleason 评分与前列腺切除术病理分级不符的临床因素,并建立了一个预测低估分级概率的模型。

材料与方法

我们分析了 1988 年至 2007 年在我们机构接受治疗的 1701 例前列腺癌患者的完整活检和病理数据。我们的分析纳入了活检 Gleason 评分 7 分及以下的患者。通过比较活检和根治性前列腺切除术的 Gleason 评分,将病例分为分级不足或分级不足。基于临床变量(种族、诊断时年龄、体重指数、前列腺重量、诊断前列腺特异性抗原、活检阳性核心与总核心比、阳性核心中最大癌症百分比和诊断至手术时间),采用逻辑回归确定低估分级的预测因素。建立了一个列线图来计算低估分级的概率。使用 bootstrap 验证结果。

结果

我们的队列中有 46.6%的病例存在分级不足。预测分级不足的显著变量是诊断时年龄、活检 Gleason 评分、诊断前列腺特异性抗原、前列腺重量、活检阳性核心与总核心比和核心中最大癌症百分比(p <0.05)。列线图预测准确性为 72.4%。

结论

使用我们的列线图可以预测 Gleason 评分低估分级的风险,达到令人满意的水平。预测分级不足将改善患者咨询,并确定那些应考虑重复活检的患者,最终提高前列腺癌诊断的准确性。

相似文献

1
Factors predicting prostatic biopsy Gleason sum under grading.预测前列腺活检 Gleason 评分的因素。
J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.
2
Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores.通过增加经直肠活检针芯数量提高预测前列腺癌Gleason评分的准确性。
Urol Int. 2007;79(4):302-6. doi: 10.1159/000109713.
3
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.在重复活检时诊断出的前列腺癌体积较小,且高级别癌的可能性较低。
J Urol. 2008 Oct;180(4):1325-9; discussion 1329. doi: 10.1016/j.juro.2008.06.022. Epub 2008 Aug 15.
4
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.预测前列腺癌根治性前列腺切除术后早期复发概率的列线图。
J Urol. 2009 Feb;181(2):601-7; discussion 607-8. doi: 10.1016/j.juro.2008.10.033. Epub 2008 Dec 13.
5
The independent impact of extended pattern biopsy on prostate cancer stage migration.扩展模式活检对前列腺癌分期迁移的独立影响。
J Urol. 2005 Nov;174(5):1789-93; discussion 1793. doi: 10.1097/01.ju.0000177465.11299.02.
6
Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.活检组织条数量是低风险前列腺癌患者临床显著 Gleason 评分升级的最重要预测因素之一。
Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.
7
Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.前列腺穿刺活检:多个变量可预测根治性前列腺切除术标本中的最终肿瘤体积。
Cancer. 2004 Aug 1;101(3):527-32. doi: 10.1002/cncr.20415.
8
Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.前列腺穿刺活检组织中癌灶所占百分比是前列腺癌根治术后前列腺特异性抗原复发的重要独立预测因素:来自SEARCH数据库的结果
J Urol. 2003 Jun;169(6):2136-41. doi: 10.1097/01.ju.0000065588.82511.06.
9
The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.前列腺穿刺活检标本中癌阳性核心的百分比强烈预测根治性前列腺切除术中的肿瘤分期和体积。
J Urol. 2000 Jan;163(1):174-8.
10
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.前列腺癌根治术前的PCA3评分可预测包膜外侵犯和肿瘤体积。
J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

引用本文的文献

1
Combined Systematic and MRI-US Fusion Prostate Biopsy Has the Highest Grading Accuracy When Compared to Final Pathology.与最终病理相比,联合系统和 MRI-US 融合前列腺活检具有最高的分级准确性。
Medicina (Kaunas). 2021 May 22;57(6):519. doi: 10.3390/medicina57060519.
2
Re; Singh S, Patil S, Tamhankar AS, Ahluwalia P, Gautam G. Low-risk prostate cancer in India: Is active surveillance a valid treatment option? Indian J Urol 2020;36:184-90.关于;辛格 S、帕蒂尔 S、坦汉卡尔 A.S、阿卢瓦利亚 P、高塔姆 G。印度的低风险前列腺癌:主动监测是一种有效的治疗选择吗?《印度泌尿外科杂志》2020 年;36:184 - 90。
Indian J Urol. 2020 Oct-Dec;36(4):331-332. doi: 10.4103/iju.IJU_386_20. Epub 2020 Oct 1.
3
Limitations and Prospects for Diffusion-Weighted MRI of the Prostate.
前列腺弥散加权 MRI 的局限性和展望。
Diagnostics (Basel). 2016 May 27;6(2):21. doi: 10.3390/diagnostics6020021.
4
Refining treatment for the men who need it: lessons from the PIVOT trial.为有需要的男性优化治疗:来自PIVOT试验的经验教训。
Transl Androl Urol. 2013 Jun;2(2):82-4. doi: 10.3978/j.issn.2223-4683.2012.09.05.
5
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.新诊断前列腺癌患者骨扫描范围变窄:一项回顾性对比研究。
Urol Ann. 2015 Apr-Jun;7(2):193-8. doi: 10.4103/0974-7796.150479.
6
Does the time from biopsy to radical prostatectomy affect Gleason score upgrading in patients with clinical t1c prostate cancer?对于临床T1c期前列腺癌患者,从活检到根治性前列腺切除术的时间会影响 Gleason 评分升级吗?
Korean J Urol. 2014 Jun;55(6):395-9. doi: 10.4111/kju.2014.55.6.395. Epub 2014 Jun 16.
7
A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients.用于预测中国患者临床诊断的局限性前列腺癌Gleason评分升级的列线图。
Chin J Cancer. 2014 May;33(5):241-8. doi: 10.5732/cjc.013.10137. Epub 2014 Feb 14.
8
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.前列腺特异性抗原速度风险计数可预测低风险前列腺癌患者的活检再分类。
J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20.
9
Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer.预测前列腺癌患者根治性前列腺切除术后肿瘤分级变化的临床和病理变量。
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E93-7. doi: 10.5489/cuaj.270.